Emergent BioSolutions has signed an indefinite-delivery, indefinite-quantity procurement contract with a maximum value up to $379.6M to supply RSDL – Reactive Skin Decontamination Lotion Kit – for use by all branches of the U.S. military. Emergent’s Canadian Subsidiary will serve as the sole subcontractor to deploy RSDL to the Department of Defense – DoD – through a new contract award to the Canadian Commercial Corporation. The new contract has a base year, which began in December 2022, and four single year option renewals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EBS:
- EBS Bags $380 Million Contract with U.S. Army
- Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
- Benchmark keeps Hold on Emergent after non-profit OTC naloxone competitor news
- Emergent BioSolutions: FDA accepts for review sNDA for Narcan Nasal Spray
- Emergent BioSolutions announces FDA acceptance of Narcan sNDA for review